The proteasome -- an emerging therapeutic target in cancer
Article Abstract:
A drug called bortezomib that inhibits proteasomes may be beneficial in patients with some types of cancer. This drug has already been approved by the FDA for treating multiple myeloma that has not responded to other chemotherapy drugs. The proteasome is a structure in all cells that breaks down proteins that are no longer needed.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Producing penicillin
Article Abstract:
The meagerness of the supplies of penicillin dictated its slow evolution as a chemotherapeutic agent. In the fall of 1942, Charles Pfizer Company committed to the production of penicillin, and the supply problem was on its way to resolution.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
The price tag on progress - chemotherapy for colorectal cancer
Article Abstract:
The U.S. Food and Drug Administration (FDA) approved five new drugs for metastatic colorectal cancer. The cost of the drugs for an eight-week course will be $1.2 billion for an estimated 56,000 patients.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The role of therapeutic antimicrobial mouthrinses in clinical practice: control of supragingival plaque and gingivitis
- Abstracts: Incremental treatment costs in National Cancer Institute-sponsored clinical trials. Pharmacy benefits and the use of drugs by the chronically III
- Abstracts: Improving the quality of care -- can we practice what we preach? Paying physicians for high-quality care